Menu Search
Equities

10X Genomics Inc

1KJ:MUN

10X Genomics Inc

Actions
  • Price (EUR)15.24
  • Today's Change-0.465 / -2.96%
  • Shares traded75.00
  • 1 Year change-57.99%
  • Beta--
Data delayed at least 15 minutes, as of Nov 08 2024 07:04 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

10x Genomics, Inc. is a life science technology company. The Company's integrated solutions include instruments, consumables and software for analyzing biological systems. Its Chromium platform includes its Chromium X Series, Chromium Connect and legacy Chromium Controller instruments, microfluidic chips and related consumables, which enables throughput analysis of individual biological components. Its Visium platform enables researchers to understand the spatial positions of biological analytes within tissues at high resolution. Its Xenium platform for in situ analysis is designed to give scientists the ability to not only locate and type cells in their tissue context. Its products include Chromium Single Cell Gene Expression, Chromium Single Cell Gene Expression Flex, Chromium Single Cell Immune Profiling, Chromium Single Cell assay for transposase accessible chromatin (ATAC), Chromium Single Cell Multiome ATAC + Gene Expression, Visium Spatial Gene Expression, and others.

  • Revenue in USD (TTM)629.74m
  • Net income in USD-182.55m
  • Incorporated2012
  • Employees1.26k
  • Location
    10X Genomics Inc6230 Stoneridge Mall RoadPLEASANTON 94588United StatesUSA
  • Phone+1 (925) 401-7300
  • Fax+1 (302) 655-5049
  • Websitehttps://www.10xgenomics.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.